Norethandrolone: Difference between revisions
Jump to navigation
Jump to search
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| verifiedrevid = 437192948 | |||
| IUPAC_name = (17β)-17-ethyl-17-hydroxyester-4-en-3-one | |||
| image = Norethandrolone structure.png | |||
{{ | |||
| | <!--Clinical data--> | ||
| | | tradename = | ||
| | | Drugs.com = {{drugs.com|international|norethandrolone}} | ||
| | | pregnancy_category = | ||
| | | legal_status = | ||
| | | routes_of_administration = | ||
| | |||
| | <!--Pharmacokinetic data--> | ||
| C=20 | H=30 | O=2 | | bioavailability = | ||
| excretion = | |||
<!--Identifiers--> | |||
| CAS_number = 52-78-8 | |||
| ATC_prefix = A14 | |||
| ATC_suffix = AA09 | |||
| PubChem = 5858 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 5649 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = P7W01638W6 | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D07127 | |||
<!--Chemical data--> | |||
| C=20 | H=30 | O=2 | |||
| molecular_weight = 302.451 g/mol | | molecular_weight = 302.451 g/mol | ||
| | | smiles = O=C4\C=C3/[C@@H]([C@H]2CC[C@]1([C@@H](CC[C@@]1(O)CC)[C@@H]2CC3)C)CC4 | ||
| | | InChI = 1/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1 | ||
| | | InChIKey = ZDHCJEIGTNNEMY-XGXHKTLJBJ | ||
| | | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | ||
| | | StdInChI = 1S/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1 | ||
| | | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | ||
| | | StdInChIKey = ZDHCJEIGTNNEMY-XGXHKTLJSA-N | ||
| synonyms = <small>(8''R'',9''S'',10''R'',13''S'',14''S'',17''S'')-17-Ethyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[''a'']phenanthren-3-one</small> | |||
}} | }} | ||
{{ | |||
'''Norethandrolone''' is an [[anabolic steroid]]. | __NOTOC__ | ||
{{CMG}}; {{AE}} {{STY}} | |||
==Overview== | |||
'''Norethandrolone''' is an [[anabolic steroid]]. This drug was approved for sale by the U.S. [[Food and Drug Administration]] (FDA) in 1965 under the trade name Nilevar<ref>{{cite book|last=W.|first=Llewellyn.|title=Anabolics|year=2005|pages=156}}</ref> and finds legitimate use as an [[androgen]] for cases of hormonal deficiency, treatment of patients with severe burns, after severe trauma and for certain forms of [[aplastic anemia]]. It is now only marketed in Australia, France and Switzerland, and as with all 17-alpha alkylated oral steroids, long-term use in high doses result in elevated liver enzymes and consequently [[cirrhosis]].<ref>{{cite book|last=D.|first=Lednicer.|title=Steroid Chemistry at Glance. Wiley.|year=2011|pages=67}}</ref> | |||
==References== | |||
{{reflist}} | |||
{{Anabolic steroids}} | {{Anabolic steroids}} | ||
{{Androgenics}} | |||
[[Category:Anabolic steroids]] | [[Category:Anabolic steroids]] | ||
{{ | {{gastrointestinal-drug-stub}} | ||
Latest revision as of 13:31, 11 March 2015
 | |
| Clinical data | |
|---|---|
| Synonyms | (8R,9S,10R,13S,14S,17S)-17-Ethyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H30O2 |
| Molar mass | 302.451 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sree Teja Yelamanchili, MBBS [2]
Overview
Norethandrolone is an anabolic steroid. This drug was approved for sale by the U.S. Food and Drug Administration (FDA) in 1965 under the trade name Nilevar[1] and finds legitimate use as an androgen for cases of hormonal deficiency, treatment of patients with severe burns, after severe trauma and for certain forms of aplastic anemia. It is now only marketed in Australia, France and Switzerland, and as with all 17-alpha alkylated oral steroids, long-term use in high doses result in elevated liver enzymes and consequently cirrhosis.[2]